Product Information
FENOFIBRATE 145 MG TABLET is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.1196 per EA under NDC 00378306605. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Dec 7, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the fenofibrate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
145 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378306605
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FENOFIBRATEApproval Type
Generic (ANDA)
FDA Application
ANDA202856FDA Approved
12/7/2012
TE Code
AB
On Market Since
5/14/2013
Pharmacological Classes
Price Statistics
The NADAC for FENOFIBRATE 145 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 95.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1196 per EA |
|---|---|
| All-time high | $2.8120 (Dec 11, 2013) |
| All-time low | $0.1088 (Nov 20, 2024) |
| 52-week high | $0.1214 |
| 52-week low | $0.1130 |
| Median price | $0.2159 |
| Average price | $0.5228 |
| Largest weekly change | +29.9% (Sep 23, 2020) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 5% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
fenofibrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Peroxisome Proliferator Receptor alpha Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FENOFIBRATE 145 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for FENOFIBRATE 145 MG TABLET, manufactured by Mylan Pharmaceuticals Inc., is $0.1196 per EA (NDC 00378306605), effective Sep 30, 2026.
How has the price of FENOFIBRATE 145 MG TABLET changed over time?
Over the history we have for it, the NADAC for FENOFIBRATE 145 MG TABLET has declined 95.7%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for FENOFIBRATE 145 MG TABLET?
Since Nov 28, 2013, the NADAC for FENOFIBRATE 145 MG TABLET has ranged from a low of $0.1088 (Nov 20, 2024) to a high of $2.8120 (Dec 11, 2013), with a median of $0.2159 per EA.
Are there cheaper alternatives to FENOFIBRATE 145 MG TABLET?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, FENOFIBRATE 145 MG TABLET, is $0.1131 per EA — about 5% below FENOFIBRATE 145 MG TABLET.
Who manufactures FENOFIBRATE 145 MG TABLET?
FENOFIBRATE 145 MG TABLET (NDC 00378306605) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.